tegafur has been researched along with Liver Diseases in 9 studies
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following intravenous administration of S-1, the blood concentration-time profiles of CDHP were similar between control rats and rats with hepatic dysfunction, but the half-life of tegafur was significantly prolonged." | 5.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
| "Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction." | 1.35 | Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. ( Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H, 2009) |
| " Following intravenous administration of S-1, the blood concentration-time profiles of CDHP were similar between control rats and rats with hepatic dysfunction, but the half-life of tegafur was significantly prolonged." | 1.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mukai, Y | 1 |
| Matsuyama, R | 1 |
| Koike, I | 1 |
| Kumamoto, T | 1 |
| Kaizu, H | 1 |
| Homma, Y | 1 |
| Takano, S | 1 |
| Sawada, Y | 1 |
| Sugiura, M | 1 |
| Yabushita, Y | 1 |
| Ito, E | 1 |
| Sato, M | 1 |
| Endo, I | 1 |
| Hata, M | 1 |
| Nio, Y | 1 |
| Iguchi, C | 1 |
| Itakura, M | 1 |
| Nishi, T | 1 |
| Hashimoto, K | 1 |
| Takeda, H | 1 |
| Takamura, M | 1 |
| Omori, H | 1 |
| Sato, Y | 1 |
| Koike, M | 1 |
| Endo, S | 1 |
| Yoshisue, K | 1 |
| Kanie, S | 1 |
| Nishimura, T | 1 |
| Chikamoto, J | 1 |
| Nagayama, S | 1 |
| Powis, G | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 1 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Takemura, M | 1 |
| Ohta, Y | 1 |
| Shuto, T | 1 |
| Takemura, S | 1 |
| Loo, TL | 1 |
| Benjamin, RS | 1 |
| Lu, K | 1 |
| Benvenuto, JA | 1 |
| Hall, SW | 1 |
| McKelvey, EM | 1 |
| Aoike, A | 1 |
| Hosokawa, T | 1 |
| Koyama, K | 1 |
| Rokutan, K | 1 |
| Nishi, Y | 1 |
| Yoshida, A | 1 |
| Nakamura, K | 1 |
| Kawai, K | 1 |
1 review available for tegafur and Liver Diseases
| Article | Year |
|---|---|
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Topics: Antineoplastic Agents; Aspartic Acid; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Fluoroura | 1982 |
1 trial available for tegafur and Liver Diseases
| Article | Year |
|---|---|
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
7 other studies available for tegafur and Liver Diseases
| Article | Year |
|---|---|
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; | 2019 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Con | 2009 |
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Chemical and Drug Induced Liver Injury; Dihydroura | 2009 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in man.
Topics: Antineoplastic Agents; Diffusion; Fluorouracil; Folic Acid Antagonists; Humans; Kinetics; Liver Dise | 1978 |
[Effect of fluoropyrimidine, drugs of tegafur and UFT on transplanted tumor in liver-damaged mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride Poisoning; Chemical an | 1988 |